コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 n the Randomized Aldactone Evaluation Study (RALES).
2 ironolactone initiation after publication of RALES.
3 eased >7-fold (3.0% to 21.3% P<0.0001) after RALES.
5 class correlation coefficients were 0.87 for RALE (95% CI: 0.80, 0.92), 0.86 for Brixia (95% CI: 0.76
6 class correlation coefficients were 0.87 for RALE (95% CI: 0.80, 0.92), 0.86 for Brixia (95% CI: 0.76
7 emia, low systolic blood pressure, pulmonary rales above the bases, or an exacerbation of known ische
9 hanical ventilation had significantly higher RALE and AI scores than those with recovery or without t
11 ical examination (jugular venous distention, rales, and edema) at baseline in the TOPCAT trial (Treat
12 e adjusted mortality risk with all 3 (edema, rales, and jugular venous distension) versus <3 physical
14 increased markedly after the publication of RALES, and many treated patients were at risk for hyperk
15 ongestion (jugular venous distention, edema, rales, and third heart sound) with the primary outcome (
16 Initial chest radiographs were scored for RALE, Brixia, and percentage opacification by one of thr
17 tems (radiographic assessment of lung edema [RALE], Brixia, and percentage opacification) in patients
19 ngham Criteria variables (dyspnea, pulmonary rales, cardiomegaly, interstitial or pulmonary edema on
20 n findings typical of interstitial fibrosis (rales, clubbing, or cyanosis) raised the risk of subsequ
21 r the Randomized Aldactone Evaluation Study (RALES) demonstrated a 30% mortality benefit for treating
23 f the Randomized Aldactone Evaluation Study (RALES) in national cohorts of older patients hospitalize
24 confidence interval {CI}, 1.2-4.1]), to have rales on examination (OR, 1.9 [95% CI, 1.0-3.7]), to be
26 Dyspnoea can progress to orthopnoea (with no rales on lung auscultation) accompanied by weakness, fat
28 ase, atrial fibrillation, diabetes mellitus, rales, peripheral edema, higher New York Heart Associati
29 We pooled individual patient data from the RALES (Randomized Aldactone Evaluation Study) and EMPHAS
32 litative assessment of all CXRs based on the RALE score for assessing the severity of lung involvemen
33 bstantial difference in baseline and maximum RALE scores and AI scores had a higher prevalence of dea
34 ion from 0.87 to 0.94 (95% CI 0.90-0.97) for RALE scores and from 0.82 to 0.91 (95% CI 0.87-0.95) for
36 ) and Radiographic Assessment of Lung Edema (RALE) scores from frontal chest radiographs (CXRs) for p
38 ndividual patient level meta-analysis of the RALES (spironolactone) and EMPHASIS-HF (eplerenone) tria
40 Clinical follow-up does not adhere to the RALES trial guidelines, resulting in higher complication
41 setting, we analyzed the application of the RALES trial protocol to the care of 104 patients, whom w
45 (Randomized Spironolactone Evaluation Study [RALES] trial), we noted a marked increase in widespread